Targeting bone metastatic cancer: Role of the mTOR pathway

Francesco Bertoldo, Franco Silvestris, Toni Ibrahim, Francesco Cognetti, Daniele Generali, Carla Ida Ripamonti, Dino Amadori, Marco Angelo Colleoni, Pierfranco Conte, Lucia Del Mastro, Sabino De Placido, Cinzia Ortega, Daniele Santini

Research output: Contribution to journalArticlepeer-review


One of the great challenges of cancer medicine is to develop effective treatments for bone metastatic cancer. Most patients with advanced solid tumors will develop bone metastasis and will suffer from skeletal related events associated with this disease. Although some therapies are available to manage symptoms derived from bone metastases, an effective treatment has not been developed yet.The mammalian target of rapamycin (mTOR) pathway regulates cell growth and survival. Alterations in mTOR signaling have been associated with pathological malignancies, including bone metastatic cancer. Inhibition of mTOR signaling might therefore be a promising alternative for bone metastatic cancer management. This review summarizes the current knowledge on mTOR pathway signaling in bone tissue and provides an overview on the known effects of mTOR inhibition in bone cancer, both in in vitro and in vivo models.

Original languageEnglish
Pages (from-to)248-254
Number of pages7
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number2
Publication statusPublished - Apr 2014


  • Bone metastatic cancer
  • Cellular signaling
  • Everolimus
  • MTOR
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Targeting bone metastatic cancer: Role of the mTOR pathway'. Together they form a unique fingerprint.

Cite this